MediLink Therapeutics
Jiaqiang Cai is a seasoned professional in the pharmaceutical industry, currently serving as CoFounder, CoCEO, and CSO of MediLink Therapeutics since December 2020, with a focus on conjugate drugs. Previously, Jiaqiang held the position of Deputy General Manager and Head of Chemistry at Shanghai Hansoh from March 2019 to December 2020, specializing in drug R&D. Additional experience includes leadership roles at Sichuan Kelun Pharmaceutical Co., Ltd. as Head of Innovation R&D and Deputy General Manager from November 2015 to March 2019, and as Senior Director of Medicinal Chemistry at WuXi AppTec from December 2011 to November 2015, alongside serving as Director of Medicinal Chemistry at BioDuro. Jiaqiang's academic background includes a Postdoctoral training in Medicinal and Natural Product Chemistry from UCL and a PhD in Organic Chemistry from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences.
This person is not in any teams
This person is not in any offices
MediLink Therapeutics
MediLink Therapeutics focuses on developing competitive drug conjugates internationally. With independent intellectual property rights, MediLink Therapeutics develops the next generation of conjugate technologies. The future products will provide better therapeutic windows for the unmet clinical needs. MediLink Therapeutics strives to upgrade technologies, establish diverse technology platforms for drug conjugates, and expand into new disease areas to serve global patients continuously.